Therapeutic agents and treatment methods for malaria

DATE

January 4, 2021

A therapeutic agent that prevents development of severe malaria by preventing immune evasion

Key Word : Malaria, RIFIN, LILRB1, LAIR1, severe malaria

Background / Context / Abstract:

It is said that 200-million people are infected with Plasmodium falciparum and 700 thousand people die of P. falciparum malaria annually, mainly in Africa and Southeast Asia. While the main therapeutic agent currently used for the treatment of P. falciparum malaria is artemisinin, the emergence of drug resistance to this agent is becoming a serious problem in the control of P. malaria, as was the case with chloroquine in the former generation.

Technology Overview:

The inventor obtained data suggesting that P. falciparum evades the host immune system via binding of a particular subset of RIFIN proteins (products of a polymorphic multigene family) expressed on the surface of P. falciparum-infected erythrocytes to LILRB1 and LAIR1, inhibitory receptors on the surface of immune cells. The present invention relates to a therapeutic agent that prevents development of severe malaria by specifically inhibiting interaction of LILRB1 and LAIR1 with RIFINs without inhibiting interaction with their original endogenous ligands.

Potential Applications / Potential Markets:

Vaccine (therapeutic antibody) for preventing the development of severe malaria after infection with P. falciparum

State of Development / Opportunity / Seeking:

●Opportunity
・Available for exclusive and non-exclusive licensing
・Exclusive/non-exclusive evaluation for defined period (set up for options)
・Collaborative/supportive research
●Seeking
・Licensing
・Development partner

IP Status:

PCT/JP2018/043698 (PCT applied in Japanese)

Contact:

ipm[@]uic.osaka-u.ac.jp

More Technologies